 In different animal models, tuftsin showed no toxicity when administrated intravenously or intraperitoneally.In a phase I study, tuftsin was shown to be nontoxic in adult human patients with advanced cancer when it was injected once intravenously (0.96 mg/kg body weight).Extensive augmentation of white blood counts and enhanced cytotoxicity of lymphocytes was notable.